Pexelizumab in Conjunction With Angioplasty in Acute Myocardial Infarction (APEX-AMI)

Completed · Phase 3 · Has a placebo group

Conditions studied: Acute Myocardial Infarction

In brief

In the setting of reperfusion therapy in an acute myocardial infarction using primary percutaneous intervention (PCI), the body's own inflammatory system involving the complement cascade may be harmful. This study will test the safety and efficacy of a novel complement inhibitor, pexelizumab to reduce mortality at 30 days.

Key facts

Study ID
NCT00091637
Run by
Procter and Gamble
People needed
5745
Starts
2004-04-01
Expected to finish
2007-05-01
Last updated by the study team
2023-11-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.